Hillsdale Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Hillsdale Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-510	Closed	-$420K	–	635
2023 Q3	$420K	Sell	510 -30	-6%	-$23.6K	0.04%	307
2023 Q2	$388K	Buy	+540	New	+$416K	0.04%	299
2022 Q2	–	Sell	-40	Closed	-$28K	–	608
2022 Q1	$28K	Sell	40 -1,000	-96%	-$633K	﹤0.01%	495
2021 Q4	$657K	Buy	+1,040	New	+$639K	0.04%	331
2020 Q4	–	Sell	-765	Closed	-$428K	–	649
2020 Q3	$428K	Hold	765	–	–	0.04%	356
2020 Q2	$477K	Sell	765 -200	-21%	-$114K	0.04%	332
2020 Q1	$471K	Sell	965 -355	-27%	-$146K	0.06%	302
2019 Q4	$496K	Hold	1,320	–	–	0.04%	361
2019 Q3	$366K	Hold	1,320	–	–	0.03%	393
2019 Q2	$413K	Hold	1,320	–	–	0.04%	375
2019 Q1	$542K	Buy	1,320 +20	+2%	+$8.24K	0.05%	282
2018 Q4	$486K	Hold	1,300	–	–	0.06%	212
2018 Q3	$525K	Hold	1,300	–	–	0.07%	167
2018 Q2	$448K	Buy	+1,300	New	+$407K	0.06%	207

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hillsdale Investment Management's REGN Position: Q4 2023 in Review

Hillsdale Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 510 shares — an estimated $420K sold.

Hillsdale Investment Management first reported a position in REGN in Q2 2018 and held it in 14 quarters. The position peaked at $657K in Q4 2021. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

Hillsdale Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Hillsdale Investment Management sold 510 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $420K.
Hillsdale Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2018 and held it in 14 quarters.
Hillsdale Investment Management's Regeneron Pharmaceuticals position peaked at $657K in Q4 2021.
1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Hillsdale Investment Management's 13F filing for Q4 2023, filed 9 Feb 2024.